Preparation and Evaluation of Intraperitoneal Long-Acting Oxaliplatin-Loaded Multi-Vesicular Liposomal Depot for Colorectal Cancer Treatment.
colorectal cancer
depot
early postoperative intraperitoneal chemotherapy
multivesicular liposome
oxaliplatin
sustained release
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
05 Aug 2020
05 Aug 2020
Historique:
received:
10
07
2020
revised:
31
07
2020
accepted:
03
08
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Colorectal cancer with peritoneal metastasis has a poor prognosis because of inadequate responses to systemic chemotherapy. Cytoreductive surgery followed by intraperitoneal (IP) chemotherapy using oxaliplatin has attracted attention; however, the short half-life of oxaliplatin and its rapid clearance from the peritoneal cavity limit its clinical application. Here, a multivesicular liposomal (MVL) depot of oxaliplatin was prepared for IP administration, with an expected prolonged effect. After optimization, a combination of phospholipids, cholesterol, and triolein was used based on its ability to produce MVL depots of monomodal size distribution (1-20 µm; span 1.99) with high entrapment efficiency (EE) (92.16% ± 2.17%). An initial burst release followed by a long lag phase of drug release was observed for the MVL depots system in vitro. An in vivo pharmacokinetic study mimicking the early postoperative IP chemotherapy regimen in rats showed significantly improved bioavailability, and the mean residence time of oxaliplatin after IP administration revealed that slow and continuous erosion of the MVL particles yielded a sustained drug release. Thus, oxaliplatin-loaded MVL depots presented in this study have potential for use in the treatment of colorectal cancer.
Identifiants
pubmed: 32764318
pii: pharmaceutics12080736
doi: 10.3390/pharmaceutics12080736
pmc: PMC7466130
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2017R1A2B2011520, NRF-2019R1I1A1A01058889, and NRF-2019R1F1A1056350
Organisme : Yonsei University College of Medicine
ID : 6-2019-0179
Organisme : University- Centered Labs
ID : 2018R1A6A1A03023718
Références
Am J Cancer Res. 2018 May 01;8(5):824-834
pubmed: 29888105
J Surg Oncol. 2013 Mar;107(4):307-11
pubmed: 22811275
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S873-9
pubmed: 26100819
Pharmaceutics. 2020 Jun 17;12(6):
pubmed: 32560359
Pharmaceutics. 2019 Aug 05;11(8):
pubmed: 31387217
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
J Mater Chem B. 2013 Sep 28;1(36):4619-4627
pubmed: 32261205
Biochim Biophys Acta. 1983 Mar 9;728(3):339-48
pubmed: 6824663
Prog Lipid Res. 2002 Sep;41(5):392-406
pubmed: 12121719
Pharm Dev Technol. 2013 Jul-Aug;18(4):828-33
pubmed: 22759074
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
Cancer Treat Rev. 2001 Dec;27(6):365-74
pubmed: 11908929
Hum Reprod Update. 2001 Nov-Dec;7(6):567-76
pubmed: 11727865
J Pharm Sci. 1995 Sep;84(9):1113-9
pubmed: 8537891
J Pharmacol Exp Ther. 2008 Dec;327(3):673-82
pubmed: 18780831
J Control Release. 2000 Feb 14;64(1-3):155-66
pubmed: 10640654
Ann Surg. 2007 May;245(5):819-24
pubmed: 17457177
Cancer Sci. 2018 Jan;109(1):94-102
pubmed: 29034540
PLoS One. 2016 Jul 14;11(7):e0158517
pubmed: 27415823
Drug Deliv. 2011 Jul;18(5):361-6
pubmed: 21428705
Br J Surg. 2000 Aug;87(8):1006-15
pubmed: 10931042
J Drug Deliv. 2011;2011:467429
pubmed: 22013534
Gastroenterol Clin Biol. 2006 Oct;30(10):1200-4
pubmed: 17075479
J Control Release. 2016 Sep 28;238:10-21
pubmed: 27432750
Sci Rep. 2017 Nov 13;7(1):15443
pubmed: 29133897
J Phys Chem B. 2008 Sep 4;112(35):10765-8
pubmed: 18698718
Int J Pharm. 2019 Jun 30;565:50-58
pubmed: 31022502
Drug Deliv. 2007 Aug;14(6):327-35
pubmed: 17701522
Eur J Pharm Biopharm. 2000 Nov;50(3):357-64
pubmed: 11072192
J Surg Oncol. 2001 Feb;76(2):106-14
pubmed: 11223836
Int J Hyperthermia. 2016 May;32(3):281-8
pubmed: 26862667
Hepatogastroenterology. 1994 Jun;41(3):207-13
pubmed: 7959539
J Pharm Sci. 1998 Nov;87(11):1341-6
pubmed: 9811487
Int J Nanomedicine. 2016 Jul 12;11:3111-29
pubmed: 27471381
Int J Pharm. 2017 Aug 30;529(1-2):608-616
pubmed: 28694094
JAMA Oncol. 2016 Sep 1;2(9):1162-9
pubmed: 27270348
Cancer Res. 1990 Sep 15;50(18):5790-4
pubmed: 2118420
Evid Based Complement Alternat Med. 2019 Dec 27;2019:7564232
pubmed: 31949471
Ann Oncol. 2002 Feb;13(2):267-72
pubmed: 11886004
J Control Release. 2019 Jan 28;294:279-287
pubmed: 30576748
Mol Med Rep. 2017 May;15(5):2795-2801
pubmed: 28447739
J Gastrointest Oncol. 2016 Feb;7(1):45-57
pubmed: 26941983
Clin Cancer Res. 2000 Apr;6(4):1205-18
pubmed: 10778943
Arch Pharm Res. 2005 Aug;28(8):988-94
pubmed: 16178428
Pharmaceutics. 2019 Nov 08;11(11):
pubmed: 31717352
Ann Surg. 2011 Jul;254(1):138-44
pubmed: 21494122
J Clin Oncol. 1998 Aug;16(8):2739-44
pubmed: 9704726
Biochem Biophys Res Commun. 2017 Aug 26;490(3):1132-1138
pubmed: 28676400
Sci Rep. 2017 Jun 22;7(1):4073
pubmed: 28642473
J Pharm Sci. 2004 Jul;93(7):1718-24
pubmed: 15176061